Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
Journal Information
Full Title: Br J Clin Pharmacol
Abbreviation: Br J Clin Pharmacol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"COMPETING INTERESTS A.Meng, K.A., C.N., L.N., S.M.C., B.K., B.B. and A.Mathias are/were employees and shareholders of Gilead Sciences, Inc. F.B., P.C. and C.C. were under a work contract with Gilead Sciences, Inc. when this research work was conducted."
Funding Disclosure
Evidence found in paper:
"Funding information Galapagos NV; Gilead Sciences"
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025